Bone Tumors Flashcards
Sternberg, JVIM, 2013:
Appendicular OSA
Association between absolute tumor burden and serum bone-specific ALP (BALP)?
Sternberg, JVIM, 2013:
Tumor burden is a determinant of serum BALP activity
Amsellem, JAVMA, 2014:
Appendicular OSA in small breed dogs
- Overall MST?
- MST and DFI in amputation-only group vs curative-intent group?
- Is total serum ALP activity prior to treatment associated with outcome?
- Difference between appendicular OSA in small breed dogs and large breed dogs?
Amsellem, JAVMA, 2014:
- Overall MST: 263 days
- MST and DFI no different between amputation-only group and curative-intent group
- No
- Appendicular OSA in small breed dogs appeared to have lower mitotic index and grade
Culp, JAVMA, 2014:
OSA
- Most common tumor location?
- What % of dogs that developed SSI after limb-sparing surgery had a significantly improved prognosis?
- What % developed metastatic disease?
- If a dog with appendicular OSA survived >1 year, what was its MST?
- Was MST affected by the addition of chemotherapy or the type of surgery or both?
Culp, JAVMA, 2014:
- Most common tumor location was the distal radius (60%)
- 69% of dogs that developed a SSI after limb-sparing surgery had an improved prognosis
- 54% developed metastatic disease
- If a dog survived >1 year, its MST was 20 months
- MST was affected by the addition of chemotherapy but not the type of surgery
Talbott, Vet Surg, 2017:
What size of lesions were identified on CT but not on 3-view thoracic radiographs?
Talbott, Vet Surg, 2017:
Lesions 2-5mm in diameter were identified on CT but not thoracic radiographs
Steffey, Vet Surg, 2017:
- Mechanism of failure of OSA-affected antebrachia vs unaffected antebrachia?
- Mechanical properties of OSA-affected antebrachia vs unaffected antebrachia?
Steffey, Vet Surg, 2017:
- OSA-affected antebrachia failed by fracture at or adjacent to the OSA by crushing and/or bending, whereas normal antebrachia failed via mid-diaphysial fracture with a transverse cranial component and an oblique caudal component
- OSA-affected antebrachia were markedly weaker, more compliant and absorbed less energy to yield and failure compared to normal antebrachia
Turner, JAVMA, 2017:
Stage III OSA
- How did metastasectomy affect MST?
- In what situation(s) did pulmonary metastasectomy provide a survival advantage?
- What tumor location was associated with a shorter DFI and overall survival time?
Turner, JAVMA, 2017:
- Metastasectomy was associated with a longer MST
- Pulmonary metastasectomy offered a survival advantage if there were <3 nodules on thoracic radiography and a DFI of >275 days, but not if there was metastasis to viscera other than lungs
- Tumor location in the proximal humerus was associated with a shorter DFI and overall survival time
Matsuyama, JAVMA, 2018:
Limb amputation + carboplatin chemotherapy + metronomic cyclophosphamide chemotherapy for appendicular OSA
- What did 58% of the dogs that received metronomic cyclophosphamide chemotherapy develop?
- What effect did metronomic cyclophosphamide chemotherapy have on median DFI and overall survival time?
Matsuyama, JAVMA, 2018:
- 58% developed cystitis
- No effect on median DFI or overall survival time
Santamaria, JAVMA, 2019:
Limb amputation + single subcutaneous infusion of carboplatin for appendicular OSA
- MST?
- DFI?
- What adverse effect(s) of chemotherapy did 7% of the dogs develop?
- Any benefit over limb amputation alone?
Santamaria, JAVMA, 2019:
- MST 196 days
- DFI 197 days
- GI signs in 7% of the dogs
- No benefit in MST over limb amputation alone
Parachini-Winter, JVIM, 2019:
Cutaneous and subcutaneous metastasis of appendicular OSA
- What % had incidental finding of cutaneous and subcutaneous metastasis?
- What % developed pulmonary metastasis and what % developed bone metastasis?
- Median cutaneous and subcutaneous metastasis-free interval?
- Median cutaneous and subcutaneous metastasis survival time?
- Prognosis after diagnosis of cutaneous and subcutaneous metastasis?
Parachini-Winter, JVIM, 2019:
- 95% incidental finding of cutaneous and subcutaneous metastasis
- 85% developed pulmonary metastasis and 5% developed bone metastasis
- Median CSM-free interval: 160 days
- Median CSM survival time: 55 days
- Grave prognosis
Selmic, JAVMA, 2014:
OSA of the maxilla, mandible and calvarium
- What % were osteoblastic OSA and what % were chondroblastic OSA
- What was associated with a decreased hazard of developing progression or recurrence and death?
- Tumors arising from which location were associated with a greater hazard of developing progression or recurrence?
- What hematological finding was associated with an increased hazard of death?
- Did concurrent chemotherapy decrease the hazard of disease progression or death?
- What % developed local progression or recurrence of disease and what % of these also subsequently developed metastatic disease?
Selmic, JAVMA, 2014:
- 69% osteoblastic OSA, 18% chondroblastic OSA
- Complete excision was associated with a decreased hazard of developing progression or recurrence and death
- Tumors arising from the calvarium were associated with a greater hazard of developing progression or recurrence
- Monocytosis was associated with an increased hazard of death
- Concurrent chemotherapy did not decrease the hazard of disease progression or death
- 51% developed local progression or recurrence of disease and 39% of these also subsequently developed metastatic disease
Giuffrida, Vet Surg, 2018:
Primary appendicular HSA vs telangiectatic OSA (tOSA)
- Distribution of HSA vs tOSA?
- Risk factor(s) for tOSA?
- Which tumor is more likely to cause lameness and which tumor is more likely to cause limb swelling?
- Rate of pulmonary metastasis for HSA vs tOSA?
- Overall survival time for tOSA treated with local treatment + chemo vs local treatment alone vs no treatment?
- Overall survival time for HSA treated with local treatment + chemo vs local treatment alone?
- More aggressive treatment with associated with longer survival time in dogs with which tumor?
Giuffrida, Vet Surg, 2018:
- HSA: 78% in the hindlimbs - proximal tibia > mid-tibia > proximal femur
tOSA: 83% in the forelimbs - proximal humerus > distal radius - Odds of tOSA increased 1.6-fold for each 5kg increase in body weight
- HSA was more likely to cause lameness but tOSA was more likely to cause limb swelling
- Pulmonary metastasis: 20% of HSA vs 7% of tOSA
- Overall survival times for tOSA: 7 months for local treatment + chemo vs 4.5 months for local treatment alone vs 3 months for no treatment
- Overall survival times for HSA: 10 months for local treatment + chemo vs 3.5 months for local treatment alone
- More aggressive treatment was associated with longer survival in dogs with HSA but not tOSA
Burton, JAVMA, 2015:
Implant-associated neoplasia
- Median time from surgical implant placement to diagnosis of neoplasia?
- What % experienced complications during healing of the initial surgery?
- What % of the implant-associated neoplasia were OSA?
- In what region of the bone were 81% of the tumors located?
Burton, JAVMA, 2015:
- 5.5 years from time of surgical implant placement to diagnosis of neoplasia
- 50% had experienced complications during healing of the initial surgery
- 81% were OSA
- 81% of the tumors were in the diaphysis
Covey, Vet Surg, 2014: Stereotactic radiotherapy (SRT) and fractures in dogs with appendicular OSA
- What % had pathological fractures before SRT and what % developed pathologic fractures after SRT?
- Metastatic rate?
- What % developed deep tissue infection?
- Survival time?
- On average, how long after SRT did fractures develop?
Covey, Vet Surg, 2014:
- 33% had fractures before SRT and 76% developed fractures after SRT
- 67% metastatic rate
- 83% developed deep tissue infection
- Survival time: 364-897 days
- Post-SRT fractures occurred an average of 6 months post-SRT, which corresponds to the expected peak time of increased bone porosity and loss of strength after a single high dose irradiation
Mitchell, Vet Surg, 2016:
2 generations of metal endoprosthesis for limb-sparing surgery
- Overall complication rate?
- Metastatic rate?
- MST?
Mitchell, Vet Surg, 2016:
- 96% overall complication rate
- 67% metastatic rate
- MST: 289 days
Petazzoni, VCOT, 2016:
Contralateral bone widening and transfer for limb-sparing surgery
- How much shorter than the contralateral tibia was the affected tibia?
- How was ROM in the stifle and tarsus affected?
Petazzoni, VCOT, 2016:
- The affected tibia was 11% shorter than the contralateral tibia
- 10 degree loss of passive ROM in the stifle and 12 degree loss of ROM in the tarsus